Clinical Trial Update: Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluated nighttime dosing of sublingual tizanidine (12 mg) for spasticity in patients with multiple sclerosis; the study has complet…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• TIZANIDINE (TIZANIDINE)

Snippet

Sponsor: Teva GTC | Conditions: Muscle Spasticity | Phase 1, Phase 2 | Status: COMPLETED